ACE-031 0.5 mg/kg q4wk + ACE-031 1.0 mg/kg q2wk
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Duchenne Muscular Dystrophy
Conditions
Duchenne Muscular Dystrophy
Trial Timeline
Apr 1, 2010 → Jun 1, 2011
NCT ID
NCT01099761About ACE-031 0.5 mg/kg q4wk + ACE-031 1.0 mg/kg q2wk
ACE-031 0.5 mg/kg q4wk + ACE-031 1.0 mg/kg q2wk is a phase 2 stage product being developed by Merck for Duchenne Muscular Dystrophy. The current trial status is terminated. This product is registered under clinical trial identifier NCT01099761. Target conditions include Duchenne Muscular Dystrophy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01099761 | Phase 2 | Terminated |
Competing Products
20 competing products in Duchenne Muscular Dystrophy